---
title: "HBV_pathway"
slug: "hbvpathway"
prefix: "hbv.pathway"
date: "2023-10-06"
enableToc: false
tags:
  - building
  - plan
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Chart template-of-breast cancer]]

# HBV prophylaxis in chemotherapy

- moderate risk: HBsAg-positive individuals receieved cytotoxic chemotherapy
- confirm HBV/HCV profiles prior to administering preventive anti-viral agents for HBV flare-up prophylaxis during chemotherapy.
- start entecavir concurrently or prior to initiating chemotherapy
  - maintained for at least 6 months after withdrawal of immunosuppression
  - duration of chemotherapy: `___`/`___`/`___` to `___`/`___`/`___` (estimated)
  - explain adverse effects:
    - headache, fatigue, dizziness, nausea reported in 22% of patients.
- monitor if HBV reactivation:
  - previously had undetectable HBV DNA -> detectable HBV DNA
  - 10x to 100x fold increase in HBV DNA
  - HBsAg negative/anti-HBc positive becomes HBsAg positive


[[test_link.md|test_link]]

[[wow_the_book.md|wow_the_book]]
